Evidence map›Paper›PMID 42461033›Full record

ArticleMicrobiology spectrum2026

Non-uniform susceptibility profiles observed in

Germán G Vargas-Cuebas, Kevin P C Minbiole, William M Wuest

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Germán G Vargas-CuebasDepartment of Chemistry, Emory University, Atlanta, Georgia, USA.ORCID 0000-0002-8906-032X
Kevin P C MinbioleDepartment of Chemistry and Biochemistry, Villanova University, Villanova, Pennsylvania, USA.ORCID 0000-0003-4263-9833
William M WuestDepartment of Chemistry, Emory University, Atlanta, Georgia, USA.ORCID 0000-0002-5198-7744

Funding

Natural Product-Inspired Approaches Toward The Development Of Antivirulence And Species-Specific InhibitorsR35GM119426 · NIGMS · TEMPLE UNIV OF THE COMMONWEALTH · PI William M Wuest · 2016 to 2026
$4.8M
The Development of Novel Disinfectants to Overcome Bacterial ResistanceR15AI185860 · NIAID · VILLANOVA UNIVERSITY · PI MINBIOLE, KEVIN P · 2024 to 2024
$359k
Investigating the impact of collagenase in Clostridioides difficile pathogenesisF31DK126467 · NIDDK · EMORY UNIVERSITY · PI VARGAS-CUEBAS, GERMAN GABRIEL · 2020 to 2024
$141k
National Institute of Allergy and Infectious Diseases AI185860NIAID NIH HHS R15 AI185860NIDDK NIH HHS DK126467NIDDK NIH HHS F31 DK126467NIGMS NIH HHS GM119426NIGMS NIH HHS R35 GM119426
6 · The paper itself

Abstract

Heteroresistance, a phenotype of bacterial subpopulations that display differential susceptibility to antimicrobial agents, is a pressing problem that results in antibiotic treatment failure and potentially in resistance development. However, this phenotype remains largely unexplored in the context of biocides. Here, using population analysis profiling (PAP) assays, we investigated susceptibility patterns in

Indexed as

Acinetobacter baumanniiAnti-Bacterial AgentsDisinfectantsPseudomonas aeruginosaStaphylococcus aureusCationsDrug Resistance, BacterialHumansMicrobial Sensitivity TestsAnti-Bacterial AgentsCationsDisinfectantsantimicrobial resistancedisinfectanteffluxheteroresistance

Identifiers

PMID42461033
PMCPMC13436339

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.